Abstract
Background:To evaluate the clinical efficacy of Simvastatin, a HMG-CoA reductase inhibitor, we observed the changes of clinical characteristics and lipid profiles after Simvastatin administration in patients with hypercholesterolemia. Methods and Results:Simvastatin 10mg was given once daily for 12 weeks in 35 patients(60± 6.0 years;14 male, 21 female with hypercholesterolemia. High density lipoprotein-cholesterol(HDL- C was increased from 38±10 to 45±9mg/dl(p<0.05. Simvastatin significantly decreased total cho- lesterol(TC from 235±15 to 181±21mg/dl(23.0%, low-density lipoprotein cholesterol(LDL-C from 164±19 to 104±18mg/dl(36.5%, TC/HDL-C from 7.0±2.0 to 4.4±1.1, LDL-C/HDL-C from 4.9±1.7 to 2.5±0.8(p<0.01 respectively. Apo B was decreased by 31%(119±19 to 87±15mg/dl, apo B/A1 ratio was decreased by 41%(1.2±0.2 to 0.7±0.2 and lipoprotein(a decreased by 12%(33 ±22 to 29±17, while apo A1 was increased by 25%(104±18 to 130±23mg/dl, p<0.01 respectively. No patients complained of chest pain, but two had skin rashes. Creatine kinase and creatinine were not changed in all patients. Conclusions:Simvastatin is an effective and well tolerated cholesterol lowering agent in patients with hypercholesterolemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
